Detection of breast carcinoma with an ICG enhanced optical imaging device in breast cancer patients.
Completed
- Conditions
- breast cancerlumpectomy1000629110006295
- Registration Number
- NL-OMON33137
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Women above the age of 21 who have biopsy-proven breast cancer stage I-II who are undergoing lumpectomy
Exclusion Criteria
Pregnant women, significant renal, cardiac or pulmonary disease, history of iodine allergy or anaphylactic reactinos to insect bites or medication, presence or history of hyperthyroidism
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary Objective:<br /><br>* Ergonomics and function of the imaging system - the NIRF imaging system<br /><br>should not interfere with the standard lumpectomy procedure and be used safely<br /><br>by the surgeon while detection of ICG takes place. Duration: 1,5 hour clinical<br /><br>procedure </p><br>
- Secondary Outcome Measures
Name Time Method <p>none</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ICG-enhanced optical imaging for breast carcinoma detection?
How does ICG-enhanced optical imaging compare to standard-of-care methods in breast cancer diagnostics?
Which biomarkers are associated with improved detection rates using ICG-enhanced optical imaging in breast cancer patients?
What adverse events are reported with ICG-enhanced optical imaging in breast cancer imaging studies?
Are there combination approaches involving ICG-enhanced optical imaging and other breast cancer therapies being explored?